All In Biotech

Drug Trial Radar · NCT04878432

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

39

Actual

Start

Mar 17, 2022

Primary completion

Oct 26, 2023

Study completion Sep 1, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))).

Conditions

  • Myelodysplastic Syndrome (MDS)

Interventions

  • MBG453Drug

    Solution for intravenous infusion

  • AzacitidineDrug

    Solution for subcutaneous injection or intravenous administration

  • DecitabineDrug

    Solution for intravenous administration

  • INQOVI (oral decitabine)Drug

    Tablet for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events and Serious Adverse EventsTime frame: Adverse events are reported from the first dose of study medication up to approximately 24 months plus 30 - 150 day safety follow up dependent on HMA, for a maximum timeframe of approximately 29 months.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Arizona Oncology Associates

    Tucson, Arizona

  • SCRI-Colorado Blood Cancer Institute

    Denver, Colorado

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Advent Health Orlando

    Orlando, Florida

  • Uni of Massachusetts Medical Center

    Worcester, Massachusetts

  • University Of Michigan

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Tisch Hospital NYU Langone

    New York, New York

  • Mount Sinai Medical Center

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • University Hospitals Of Cleveland

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Texas Oncology San Antonio USO

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.